$33.92
0.621.86%
At Close: -
$34.30
0.381.12%
After Hours: 4:54 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Harmony Biosciences (NASDAQ:HRMY) Stock, Analyst Ratings, Price Targets, Forecasts
Harmony Biosciences Holdings Inc has a consensus price target of $45.91 based on the ratings of 11 analysts. The high is $69 issued by Oppenheimer on May 26, 2023. The low is $27 issued by Raymond James on November 1, 2023. The 3 most-recent analyst ratings were released by Needham, Needham, and Citigroup on June 25, 2024, June 24, 2024, and June 21, 2024, respectively. With an average price target of $50.67 between Needham, Needham, and Citigroup, there's an implied 47.72% upside for Harmony Biosciences Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Citigroup
Cantor Fitzgerald
Mizuho
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Harmony Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/25/2024 | Buy Now | 51.6% | Needham | Ami Fadia | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 51.6% | Needham | Ami Fadia | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2024 | Buy Now | 39.94% | Citigroup | David Hoang | → $48 | Initiates | → Buy | Get Alert |
| 05/01/2024 | Buy Now | 51.6% | Needham | Ami Fadia | $50 → $52 | Maintains | Buy | Get Alert |
| 04/30/2024 | Buy Now | 45.77% | Needham | Ami Fadia | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | Buy Now | 42.86% | Cantor Fitzgerald | Charles Duncan | → $49 | Reiterates | Overweight → Overweight | Get Alert |
| 04/11/2024 | Buy Now | 45.77% | Needham | Ami Fadia | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 45.77% | Needham | Ami Fadia | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 42.86% | Cantor Fitzgerald | Charles Duncan | → $49 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | Buy Now | 16.62% | Mizuho | Graig Suvannavejh | $42 → $40 | Maintains | Buy | Get Alert |
| 02/23/2024 | Buy Now | 42.86% | Cantor Fitzgerald | Charles Duncan | → $49 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 45.77% | Needham | Ami Fadia | $53 → $50 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 54.52% | Needham | Ami Fadia | → $53 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 22.45% | Mizuho | Graig Suvannavejh | $33 → $42 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -18.37% | Goldman Sachs | Corinne Jenkins | $25 → $28 | Maintains | Sell | Get Alert |
| 01/02/2024 | Buy Now | -12.54% | B of A Securities | Jason Gerberry | → $30 | Downgrade | Neutral → Underperform | Get Alert |
| 11/01/2023 | Buy Now | 54.52% | Needham | Ami Fadia | → $53 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2023 | Buy Now | -21.28% | Raymond James | Danielle Brill | $26 → $27 | Maintains | Outperform | Get Alert |
| 10/16/2023 | Buy Now | 22.45% | Piper Sandler | David Amsellem | $72 → $42 | Maintains | Overweight | Get Alert |
| 10/16/2023 | Buy Now | 54.52% | Needham | Ami Fadia | $66 → $53 | Maintains | Buy | Get Alert |
| 10/16/2023 | Buy Now | -24.2% | Raymond James | Danielle Brill | $58 → $26 | Maintains | Outperform | Get Alert |
| 10/04/2023 | Buy Now | 57.43% | Mizuho | Graig Suvannavejh | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2023 | Buy Now | -9.62% | Goldman Sachs | Corinne Jenkins | $40 → $31 | Maintains | Sell | Get Alert |
| 09/25/2023 | Buy Now | -9.62% | Goldman Sachs | Corinne Jenkins | $40 → $31 | Downgrade | Neutral → Sell | Get Alert |
| 09/22/2023 | Buy Now | 92.42% | Needham | Ami Fadia | → $66 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | Buy Now | 57.43% | Mizuho | Graig Suvannavejh | $54 → $54 | Maintains | Buy | Get Alert |
| 09/07/2023 | Buy Now | 72.01% | Berenberg | Caroline Palomeque | → $59 | Initiates | → Buy | Get Alert |
| 08/29/2023 | Buy Now | 57.43% | Mizuho | Graig Suvannavejh | → $54 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | 118.66% | Cantor Fitzgerald | Charles Duncan | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 92.42% | Needham | Ami Fadia | → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 57.43% | Mizuho | Graig Suvannavejh | $60 → $54 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 92.42% | Needham | Ami Fadia | → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 69.1% | Raymond James | Danielle Brill | $62 → $58 | Maintains | Outperform | Get Alert |
| 08/01/2023 | Buy Now | 92.42% | Needham | Ami Fadia | → $66 | Reiterates | Buy → Buy | Get Alert |
| 06/23/2023 | Buy Now | 118.66% | Cantor Fitzgerald | Charles Duncan | $75 → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 06/02/2023 | Buy Now | 95.34% | Needham | Ami Fadia | → $67 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 95.34% | Needham | Ami Fadia | → $67 | Reiterates | → Buy | Get Alert |
| 05/26/2023 | Buy Now | 101.17% | Oppenheimer | Francois Brisebois | → $69 | Reiterates | Outperform → Outperform | Get Alert |
| 05/03/2023 | Buy Now | 118.66% | Cantor Fitzgerald | Charles Duncan | $71 → $75 | Maintains | Overweight | Get Alert |
| 05/03/2023 | Buy Now | 95.34% | Needham | Ami Fadia | → $67 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 2.04% | B of A Securities | Jason Gerberry | → $35 | Initiates | → Neutral | Get Alert |
| 04/17/2023 | Buy Now | 95.34% | Needham | Ami Fadia | → $67 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 74.93% | Mizuho | Graig Suvannavejh | → $60 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 74.93% | Mizuho | Graig Suvannavejh | → $60 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 25.36% | Goldman Sachs | Corinne Jenkins | $49 → $43 | Maintains | Neutral | Get Alert |
| 02/22/2023 | Buy Now | 25.36% | Goldman Sachs | Corinne Jenkins | $49 → $43 | Maintains | Neutral | Get Alert |
| 02/22/2023 | Buy Now | 74.93% | Mizuho | Graig Suvannavejh | $70 → $60 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 95.34% | Needham | Ami Fadia | $70 → $67 | Maintains | Buy | Get Alert |
| 02/21/2023 | Buy Now | 104.08% | Needham | Ami Fadia | → $70 | Reiterates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | 104.08% | Piper Sandler | David Amsellem | $62 → $70 | Maintains | Overweight | Get Alert |
| 11/08/2022 | Buy Now | 104.08% | Mizuho | Graig Suvannavejh | $60 → $70 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 80.76% | Raymond James | Danielle Brill | $60 → $62 | Maintains | Outperform | Get Alert |
| 11/02/2022 | Buy Now | 89.5% | Needham | Ami Fadia | $60 → $65 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 48.69% | Goldman Sachs | Corinne Jenkins | $58 → $51 | Maintains | Neutral | Get Alert |
| 10/14/2022 | Buy Now | 77.84% | Jefferies | Chris Howerton | $57 → $61 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2022 | Buy Now | 74.93% | Mizuho | Graig Suvannavejh | $64 → $60 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 95.34% | Oppenheimer | Francois Brisebois | $62 → $67 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 66.18% | Jefferies | Chris Howerton | → $57 | Downgrade | Buy → Hold | Get Alert |
| 08/03/2022 | Buy Now | 74.93% | Raymond James | Danielle Brill | $58 → $60 | Maintains | Outperform | Get Alert |
| 07/13/2022 | Buy Now | 60.35% | Goldman Sachs | Corinne Jenkins | → $55 | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | Buy Now | 86.59% | Mizuho | Graig Suvannavejh | → $64 | Initiates | → Buy | Get Alert |
| 06/29/2022 | Buy Now | 80.76% | Oppenheimer | Francois Brisebois | $55 → $62 | Maintains | Outperform | Get Alert |
| 04/14/2022 | Buy Now | 83.67% | Cantor Fitzgerald | Charles Duncan | → $63 | Initiates | → Overweight | Get Alert |
| 12/01/2021 | Buy Now | 60.35% | Oppenheimer | Francois Brisebois | — | Initiates | → Outperform | Get Alert |
| 11/04/2021 | Buy Now | 69.1% | Raymond James | Danielle Brill | — | Initiates | → Outperform | Get Alert |
| 09/23/2021 | Buy Now | 66.18% | Needham | Ami Fadia | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Harmony Biosciences (HRMY) stock?
The latest price target for Harmony Biosciences (NASDAQ:HRMY) was reported by Needham on June 25, 2024. The analyst firm set a price target for $52.00 expecting HRMY to rise to within 12 months (a possible 51.60% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Harmony Biosciences (HRMY)?
The latest analyst rating for Harmony Biosciences (NASDAQ:HRMY) was provided by Needham, and Harmony Biosciences reiterated their buy rating.
When was the last upgrade for Harmony Biosciences (HRMY)?
The last upgrade for Harmony Biosciences Holdings Inc happened on October 14, 2022 when Jefferies raised their price target to $61. Jefferies previously had a hold for Harmony Biosciences Holdings Inc.
When was the last downgrade for Harmony Biosciences (HRMY)?
The last downgrade for Harmony Biosciences Holdings Inc happened on January 2, 2024 when B of A Securities changed their price target from N/A to $30 for Harmony Biosciences Holdings Inc.
When is the next analyst rating going to be posted or updated for Harmony Biosciences (HRMY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harmony Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harmony Biosciences was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.
Is the Analyst Rating Harmony Biosciences (HRMY) correct?
While ratings are subjective and will change, the latest Harmony Biosciences (HRMY) rating was a reiterated with a price target of $52.00 to $52.00. The current price Harmony Biosciences (HRMY) is trading at is $34.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.